tripeptide for treatment of diseases linked to increased apoptotic rates
In multicellular organisms, homeostasis is maintained through a balance between cell proliferation and cell death. Physiologic cell death occurs primarily through an evolutionarily conserved form of cell suicide termed apoptosis. It is well known that several diseases are linked to increased apoptotic rates such as, autoimmune diseases, neurodegenerative disorders, myocardial infarction, stroke or inflammatory diseases such as Crohn’s disease.
The present invention is related to the tripeptide (l)Lys-(d)Pro-(l)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an antiapoptotic effect. Results of numerous experiments (e.g. expression of cytokeratin-18 in intestinal epithelial cells in vitro) indicate that administration of KdPT leads to significantly reduced apoptotic rates.
A European patent application has been filed.
Commercial use and advantages of the invention
Use of KdPT as a new antiapoptotic agent may be indicated in treating ischemic disorders including after organ transplantation as well as cerebrovascular accidents such as ischemic stroke.
Advantages of the invention:
Though several diseases are linked to increased apoptotic rates, treatment regimes mostly are not targeting at antiapoptotic effects. Therefore, the use of KdPT as an antiapoptotic agent may exert synergistic effects in combination therapy with standard therapy.
Since KdPT is a structural related to the human a-melanocyte stimulating hormone, only few side-effects are expected.